Exact Sciences Corporation (EXAS)
USD 42.12
(-0.34%)
USD 42.12
(-0.34%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.06 Billion USD | -1.32% |
| 2022 | 2.08 Billion USD | -2.63% |
| 2021 | 2.14 Billion USD | 26.45% |
| 2020 | 1.69 Billion USD | 89.78% |
| 2019 | 893.35 Million USD | 80.13% |
| 2018 | 495.95 Million USD | 62.55% |
| 2017 | 305.1 Million USD | 36.7% |
| 2016 | 223.19 Million USD | 28.27% |
| 2015 | 174 Million USD | 77.53% |
| 2014 | 98.01 Million USD | 92.54% |
| 2013 | 50.9 Million USD | -10.36% |
| 2012 | 56.78 Million USD | 72.28% |
| 2011 | 32.96 Million USD | 92.24% |
| 2010 | 17.14 Million USD | 22.92% |
| 2009 | 13.94 Million USD | 64.05% |
| 2008 | 8.5 Million USD | -36.63% |
| 2007 | 13.41 Million USD | -23.04% |
| 2006 | 17.43 Million USD | -6.71% |
| 2005 | 18.69 Million USD | -20.94% |
| 2004 | 23.64 Million USD | -25.46% |
| 2003 | 31.71 Million USD | -0.05% |
| 2002 | 31.73 Million USD | 21.11% |
| 2001 | 26.2 Million USD | 148.36% |
| 2000 | 10.54 Million USD | 100.46% |
| 1999 | 5.26 Million USD | 30.89% |
| 1998 | 4.02 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 569.68 Million USD | 4.94% |
| 2024 Q2 | 508.01 Million USD | -10.83% |
| 2024 Q3 | 555.08 Million USD | 8.65% |
| 2023 FY | 2.05 Billion USD | -1.32% |
| 2023 Q4 | 542.86 Million USD | 19.85% |
| 2023 Q1 | 522.6 Million USD | 0.25% |
| 2023 Q2 | 541.47 Million USD | 3.61% |
| 2023 Q3 | 452.96 Million USD | -16.35% |
| 2022 Q2 | 530.03 Million USD | 0.22% |
| 2022 Q4 | 521.29 Million USD | 2.76% |
| 2022 FY | 2.08 Billion USD | -2.63% |
| 2022 Q1 | 528.88 Million USD | -8.21% |
| 2022 Q3 | 507.28 Million USD | -4.29% |
| 2021 FY | 2.14 Billion USD | 26.45% |
| 2021 Q1 | 592.59 Million USD | -24.21% |
| 2021 Q2 | 492.48 Million USD | -16.89% |
| 2021 Q3 | 482.41 Million USD | -2.05% |
| 2021 Q4 | 576.2 Million USD | 19.44% |
| 2020 Q3 | 306.98 Million USD | 18.99% |
| 2020 FY | 1.69 Billion USD | 89.78% |
| 2020 Q4 | 781.87 Million USD | 154.7% |
| 2020 Q2 | 257.98 Million USD | -25.99% |
| 2020 Q1 | 348.59 Million USD | 8.51% |
| 2019 FY | 893.35 Million USD | 80.13% |
| 2019 Q4 | 321.26 Million USD | 59.25% |
| 2019 Q3 | 201.74 Million USD | 10.77% |
| 2019 Q1 | 186.98 Million USD | 21.31% |
| 2019 Q2 | 182.12 Million USD | -2.6% |
| 2018 Q2 | 108.74 Million USD | 4.65% |
| 2018 Q1 | 103.91 Million USD | 19.38% |
| 2018 Q3 | 129.16 Million USD | 18.78% |
| 2018 Q4 | 154.13 Million USD | 19.33% |
| 2018 FY | 495.95 Million USD | 62.55% |
| 2017 Q1 | 66.9 Million USD | 13.23% |
| 2017 FY | 305.1 Million USD | 36.7% |
| 2017 Q4 | 87.04 Million USD | 8.41% |
| 2017 Q3 | 80.29 Million USD | 12.99% |
| 2017 Q2 | 71.06 Million USD | 6.22% |
| 2016 Q2 | 56.24 Million USD | 4.85% |
| 2016 Q3 | 54.23 Million USD | -3.57% |
| 2016 Q1 | 53.63 Million USD | 13.7% |
| 2016 FY | 223.19 Million USD | 28.27% |
| 2016 Q4 | 59.08 Million USD | 8.95% |
| 2015 Q3 | 48.37 Million USD | 14.11% |
| 2015 Q4 | 47.17 Million USD | -2.48% |
| 2015 Q2 | 42.39 Million USD | 17.44% |
| 2015 Q1 | 36.09 Million USD | 17.63% |
| 2015 FY | 174 Million USD | 77.53% |
| 2014 Q1 | 16.47 Million USD | 23.83% |
| 2014 FY | 98.01 Million USD | 92.54% |
| 2014 Q4 | 30.68 Million USD | -1.91% |
| 2014 Q3 | 31.28 Million USD | 59.86% |
| 2014 Q2 | 19.57 Million USD | 18.81% |
| 2013 Q2 | 13.38 Million USD | 12.18% |
| 2013 Q3 | 12.28 Million USD | -8.25% |
| 2013 Q1 | 11.93 Million USD | -20.86% |
| 2013 Q4 | 13.3 Million USD | 8.3% |
| 2013 FY | 50.9 Million USD | -10.36% |
| 2012 Q3 | 14.04 Million USD | -11.82% |
| 2012 FY | 56.78 Million USD | 72.28% |
| 2012 Q2 | 15.92 Million USD | 35.68% |
| 2012 Q4 | 15.07 Million USD | 7.36% |
| 2012 Q1 | 11.73 Million USD | 6.98% |
| 2011 Q3 | 8.87 Million USD | 15.6% |
| 2011 FY | 32.96 Million USD | 92.24% |
| 2011 Q2 | 7.67 Million USD | 41.24% |
| 2011 Q1 | 5.43 Million USD | 4.7% |
| 2011 Q4 | 10.97 Million USD | 23.61% |
| 2010 Q1 | 3.41 Million USD | 10.48% |
| 2010 Q3 | 4.74 Million USD | 25.16% |
| 2010 Q4 | 5.19 Million USD | 9.4% |
| 2010 FY | 17.14 Million USD | 22.92% |
| 2010 Q2 | 3.79 Million USD | 11.01% |
| 2009 Q3 | 2.32 Million USD | -36.99% |
| 2009 FY | 13.94 Million USD | 64.05% |
| 2009 Q4 | 3.09 Million USD | 32.87% |
| 2009 Q2 | 3.69 Million USD | -24.26% |
| 2009 Q1 | 4.87 Million USD | 151.6% |
| 2008 Q3 | 1.84 Million USD | -8.65% |
| 2008 Q4 | 1.93 Million USD | 4.87% |
| 2008 FY | 8.5 Million USD | -36.63% |
| 2008 Q1 | 2.69 Million USD | -16.9% |
| 2008 Q2 | 2.02 Million USD | -24.91% |
| 2007 Q4 | 3.24 Million USD | -12.0% |
| 2007 FY | 13.41 Million USD | -23.04% |
| 2007 Q1 | 3.31 Million USD | 3.34% |
| 2007 Q2 | 3.17 Million USD | -4.07% |
| 2007 Q3 | 3.68 Million USD | 15.89% |
| 2006 Q4 | 3.2 Million USD | -28.03% |
| 2006 FY | 17.43 Million USD | -6.71% |
| 2006 Q1 | 5.08 Million USD | 22.79% |
| 2006 Q2 | 4.68 Million USD | -7.86% |
| 2006 Q3 | 4.45 Million USD | -4.93% |
| 2005 Q4 | 4.14 Million USD | -6.73% |
| 2005 FY | 18.69 Million USD | -20.94% |
| 2005 Q3 | 4.44 Million USD | -5.55% |
| 2005 Q2 | 4.7 Million USD | -12.97% |
| 2005 Q1 | 5.4 Million USD | -7.75% |
| 2004 Q1 | 6.55 Million USD | -6.05% |
| 2004 Q2 | 5.61 Million USD | -14.36% |
| 2004 Q4 | 5.85 Million USD | 4.27% |
| 2004 Q3 | 5.61 Million USD | 0.09% |
| 2004 FY | 23.64 Million USD | -25.46% |
| 2003 Q1 | 8.45 Million USD | 10.98% |
| 2003 FY | 31.71 Million USD | -0.05% |
| 2003 Q2 | 8.41 Million USD | -0.46% |
| 2003 Q3 | 7.87 Million USD | -6.49% |
| 2003 Q4 | 6.97 Million USD | -11.36% |
| 2002 Q1 | 7.9 Million USD | 10.53% |
| 2002 Q4 | 7.61 Million USD | -5.6% |
| 2002 Q2 | 8.14 Million USD | 3.09% |
| 2002 FY | 31.73 Million USD | 21.11% |
| 2002 Q3 | 8.07 Million USD | -0.91% |
| 2001 Q2 | 6.72 Million USD | 5.6% |
| 2001 Q4 | 7.14 Million USD | 12.28% |
| 2001 Q1 | 6.36 Million USD | 0.0% |
| 2001 FY | 26.2 Million USD | 148.36% |
| 2001 Q3 | 6.36 Million USD | -5.3% |
| 2000 FY | 10.54 Million USD | 100.46% |
| 1999 FY | 5.26 Million USD | 30.89% |
| 1998 FY | 4.02 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 110.52 Million USD | -1764.311% |
| Applied DNA Sciences, Inc. | 16.48 Million USD | -12398.118% |
| Aspira Women's Health Inc. | 24.11 Million USD | -8444.953% |
| Biodesix, Inc. | 77.41 Million USD | -2561.53% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | -52423.192% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -23409.035% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -23409.035% |
| Bionano Genomics, Inc. | 148.99 Million USD | -1282.971% |
| CareDx, Inc | 277.76 Million USD | -641.817% |
| Check-Cap Ltd. | 19.28 Million USD | -10583.517% |
| Castle Biosciences, Inc. | 242.78 Million USD | -748.713% |
| DarioHealth Corp. | 62.17 Million USD | -3214.188% |
| Fulgent Genetics, Inc. | 171.9 Million USD | -1098.638% |
| Guardant Health, Inc. | 901.62 Million USD | -128.536% |
| ICON Public Limited Company | 755.64 Million USD | -172.686% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | -88.548% |
| Illumina, Inc. | 3.81 Billion USD | 45.96% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | -17498.131% |
| iSpecimen Inc. | 16.27 Million USD | -12558.945% |
| Standard BioTools Inc. | 113.48 Million USD | -1715.621% |
| MDxHealth SA | 71.25 Million USD | -2791.728% |
| 23andMe Holding Co. | 420.73 Million USD | -389.748% |
| Medpace Holdings, Inc. | 187.68 Million USD | -997.895% |
| Myriad Genetics, Inc. | 600.1 Million USD | -243.364% |
| Mainz Biomed B.V. | 27.15 Million USD | -7488.216% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | -19485.419% |
| NeoGenomics, Inc. | 341.25 Million USD | -503.815% |
| Neogen Corporation | 405.23 Million USD | -408.475% |
| Inotiv, Inc. | 246.9 Million USD | -734.55% |
| Natera, Inc. | 938.98 Million USD | -119.442% |
| OpGen, Inc. | 30.65 Million USD | -6621.028% |
| OPKO Health, Inc. | 574.68 Million USD | -258.549% |
| Psychemedics Corporation | 11.33 Million USD | -18080.078% |
| Prenetics Global Limited | 60.73 Million USD | -3292.567% |
| Prenetics Global Limited | 60.73 Million USD | -3292.567% |
| Precipio, Inc. | 13.63 Million USD | -15008.74% |
| Personalis, Inc. | 128.14 Million USD | -1507.98% |
| RadNet, Inc. | 268.87 Million USD | -666.341% |
| Sera Prognostics, Inc. | 39.91 Million USD | -5062.036% |
| Sotera Health Company | 300.46 Million USD | -585.778% |
| Neuronetics, Inc. | 82.25 Million USD | -2404.93% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -12563.041% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -12563.041% |
| Trinity Biotech plc | 46.49 Million USD | -4331.724% |
| T2 Biosystems, Inc. | 41.49 Million USD | -4865.85% |
| Twist Bioscience Corporation | 354.18 Million USD | -481.775% |
| Exagen Inc. | 52.29 Million USD | -3840.355% |